Pfizer’s Neusentis research unit near Cambridge (UK) has been shut down. That’s what I’m hearing from more than one source, although there appears (so far) to be little or no public announcement about this. To the best of my knowledge their big focus there was pain, which has been a rough therapeutic area to make a living in. It’s interesting that this is taking place while the Pfizer-Allergan deal is still in media res, but this must have been planned for a while. . .
Update: story from the Financial Times.